Phase 3 N=711 Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Acute Myeloid Leukemia
Primary: Overall Survival — 7.5; 6.1 Months — p=0.0305
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=226 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Childhood Acute Lymphoblastic Leukemia in Remission · Childhood Acute Myeloid Leukemia in Remission · Childhood Chronic Myelogenous Leukemia
Primary: Duration of Severe Oral Mucositis (WHO Grade 3 or 4) — 4.5; 4.5 Number of days
Phase 3 N=27 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Childhood Acute Lymphoblastic Leukemia in Remission · Childhood Acute Myeloid Leukemia in Remission · Childhood Chronic Myelogenous Leukemia
Primary: Estimated Two-year Event-free Survival (EFS) — 66; 83 Percentage of patients
Phase 3 N=87 Brain Imaging and Treatment Studies of the Night Eating Syndrome
Night Eating Syndrome
Primary: Change in Symptoms of NES — 46.1; 11.8; 17.4; NA percentage of calories after dinner
Phase 3 N=22 Stem Cell Transplant for Hemoglobinopathy
Sickle Cell Disease · Thalassemia · Severe Congenital Neutropenia
Primary: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity — 0; 0; 2 Participants
Phase 3 N=155 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Head and Neck Cancer · Mucositis · Oral Complications of Radiation Therapy
Primary: Total Pain Reduction (Mouth and Throat) — -9.1; -4.7 units on a scale — p=<0.001
Phase 3 N=283 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Macular Edema Secondary to Branch Retinal Vein Occlusion
Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001
Phase 3 N=544 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Lung Cancer · Radiation Toxicity
Primary: Overall Survival — 28.7; 20.3; 25.0; 24.0 months — p=0.0042
Phase 3 N=56 Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
Nocturia
Primary: The Pearson Correlation Coefficient Between Change From Baseline to Month 1 in Number of Nocturnal Voids and Change From Baseline to Month 1 in Nocturia Impact (NI)…
Phase 3 N=18 Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion
Healthy · Hypoxia
Primary: SpO2 Accuracy During Motion Conditions - MaxA Sensor — 1.78 Accuracy Root Mean Square
Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Phase 3 N=515 Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Heart Failure, Congestive
Primary: Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio…
Phase 3 N=112 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
Cervical Dystonia
Primary: TWSTRS Total Score at Week 4 and Week 12 for Treatment Cycles 1, 2 and 3. — 37.7; 30.1; 32.6; 27.0 units on a scale
Phase 3 N=30 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan Syndrome
Primary: Central Aortic Distensibility by MRI — 3.7; 4.7; 5.7; 5.1 (mmHg ^ -1) x 10 ^ -3
Phase 3 N=551 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
Asthma
Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001